News from sorrento therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 12, 2014, 11:00 ET

Sorrento To Present At The 2014 Stifel Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present...

Oct 16, 2014, 06:27 ET

Los datos del estudio TRIBECA apoyan el potencial de la bioequivalencia entre Cynviloq y paclitaxel

- Los datos farmacocinéticos iniciales del estudio TRIBECA apoyan el potencial de la bioequivalencia entre Cynviloq y paclitaxel...

Oct 15, 2014, 16:17 ET

Les données pharmacocinétiques initiales de l'étude TRIBECA confirment le potentiel de bioéquivalence entre Cynviloq et le paclitaxel lié à de l'albumine

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), une société de produits oncologiques développant de nouveaux traitements...

Oct 15, 2014, 07:55 ET

Erste pharmakokinetische Daten aus TRIBECA-Studie stützen potenzielle Bioäquivalenz zwischen Cynviloq und Albumin-gebundenem Paclitaxel

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), ein Onkologieunternehmen, das neue Behandlungsmethoden für Krebs sowie für die...

Oct 14, 2014, 16:00 ET

Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain,...

Oct 03, 2014, 14:41 ET

Sorrento and Lee's Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Sep 05, 2014, 08:45 ET

Sorrento Therapeutics to Present at Two Healthcare Conferences

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 26, 2014, 08:45 ET

Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 18, 2014, 07:45 ET

Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 08, 2014, 17:00 ET

Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jul 31, 2014, 17:38 ET

Sorrento Announces the Unexpected Death of its Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice...

Jul 21, 2014, 08:45 ET

Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jul 01, 2014, 08:45 ET

Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 25, 2014, 08:45 ET

Morphotek and Sorrento Therapeutics Sign an Exclusive Research and Option Agreement to Generate and Develop Morphotek Antibody Drug Conjugates

Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company...

Jun 23, 2014, 08:45 ET

Sorrento Therapeutics Announces Confidential Submission of Draft Registration Statement for Initial Public Offering (IPO) of its Wholly-owned Subsidiary Ark Animal Health with the SEC

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 20, 2014, 15:15 ET

Sorrento to Present at BIO Business Forum

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), a late-stage clinical oncology company developing new treatments for cancer and its...

Jun 12, 2014, 20:30 ET

Sorrento Announces Underwriters' Exercise of Over-Allotment Option

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 30, 2014, 13:49 ET

Sorrento Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...

May 14, 2014, 23:57 ET

Sorrento Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...

May 14, 2014, 16:40 ET

Sorrento Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...